Effect of VKORC1 - 1639 G > A polymorphism, body weight, age, and serum albumin alterations on warfarin response in Japanese patients

Thrombosis Research

Volumn 124, Issue 2, 2009, Pages 161-166

  Yoshizawa, Misa ^a   Hayashi, Hideki ^a   Tashiro, Yoshio ^b   Sakawa, Sonoko ^a   Moriwaki, Hideaki ^b   Akimoto, Takehide ^b   Doi, Osamu ^b   Kimura, Midori ^b   Kawarasaki, Yoshinori ^b   Inoue, Kazuyuki ^a   Itoh, Kunihiko ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b SHIZUOKA GENERAL HOSPITAL   (Japan)

Author keywords

CYP2C9; Dosing algorithm; Genetic polymorphisms; Retrospective analysis; VKORC1; Warfarin

Indexed keywords

ALBUMIN; CYTOCHROME P450 2C9; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); WARFARIN;

ADULT; AGE; AGED; ALBUMIN BLOOD LEVEL; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENETIC ANALYSIS; GENETIC VARIABILITY; HEART ATRIUM THROMBOSIS; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAPANESE; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTHROMBIN TIME; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOSIS PREVENTION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BODY WEIGHT; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; JAPAN; LINEAR MODELS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; SERUM ALBUMIN; WARFARIN;

EID: 67249147218     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.11.011     Document Type: Article

References (32)

1. Nelsestuen G.L., Zytkovicz T.H., and Howard J.B. The mode of action of vitamin K. Identification of gamma-carboxyglutamic acid as a component of prothrombin. J Biol Chem 249 (1974) 6347-6350
2. Stenflo J., Fernlund P., Egan W., and Roepstorff P. Vitamin K dependent modifications of glutamic acid residues in prothrombin. Proc Natl Acad Sci U S A 71 (1974) 2730-2733
3. Suttie J.W. The biochemical basis of warfarin therapy. Adv Exp Med Biol 214 (1987) 3-16
4. Zimmermann A., and Matschiner J.T. Biochemical basis of hereditary resistance to warfarin in the rat. Biochem Pharmacol 23 (1974) 1033-1040
5. D Andrea G., D R.L., Ambrosio, Di Perna P., Chetta M., Santacroce R., Brancaccio V., et al. A polymorphism in the VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 105 (2005) 645-649
6. Rost S., Fregin A., Ivaskevicius V., Conzelmann E., Hortnagel K., Pelz H.J., et al. Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427 (2004) 537-541
7. Li T., Chang C.Y., Jin D.Y., Lin P.J., Khvorova A., and Stafford D.W. Identification of the gene for vitamin K epoxide reductase. Nature 427 (2004) 541-544
8. Rieder M.J., Reiner A.P., Gage B.F., Nickerson D.A., Eby C.S., McLeod H.L., et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352 (2005) 2285-2293
9. Yuan H.Y., Chen J.J., Lee M.T., Wung J.C., Chen Y.F., Charng M.J., et al. A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14 (2005) 1745-1751
10. Kaminsky L.S., and Zhang Z.Y. Human P450 metabolism of warfarin. Pharmacol Ther 73 (1997) 67-74
11. Meehan R.R., Gosden J.R., Rout D., Hastie N.D., Friedberg T., Adesnik M., et al. Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. Am J Hum Genet 42 (1988) 26-37
12. Goldstein J.A., and de Morais S.M. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 4 (1994) 285-299
13. Yin T., and Miyata T. Warfarin dose and the pharmacogenomics of CYP2C9 and VKORC1 - rationale and perspectives. Thromb Res 120 (2007) 1-10
14. Sundberg MIDA, Nebert DW. vol. Available from: http://www.imm.ki.se/CYPalleles.
15. Higashi M.K., Veenstra D.L., Kondo L.M., Wittkowsky A.K., Srinouanprachanh S.L., Farin F.M., et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA 287 (2002) 1690-1698
16. Yamazaki H., Inoue K., Chiba K., Ozawa N., Kawai T., Suzuki Y., et al. Comparative studies on the catalytic roles of cytochrome P450 2C9 and its Cys- and Leu-variants in the oxidation of warfarin, flurbiprofen, and diclofenac by human liver microsomes. Biochem Pharmacol 56 (1998) 243-251
17. Rettie A.E., Wienkers L.C., Gonzalez F.J., Trager W.F., and Korzekwa K.R. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4 (1994) 39-42
18. Sullivan-Klose T.H., Ghanayem B.I., Bell D.A., Zhang Z.Y., Kaminsky L.S., et al. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics 6 (1996) 341-349
19. Aithal G.P., Day C.P., Kesteven P.J., and Daly A.K. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353 (1999) 717-719
20. Vladutiu G.D. The FDA announces new drug labeling for pharmacogenetic testing: is personalized medicine becoming a reality?. Mol Genet Metab 93 (2008) 1-4
21. Sconce E.A., Khan T.I., Wynne H.A., Avery P., Monkhouse L., King B.P., et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106 (2005) 2329-2333
22. Moridani M., Fu L., Selby R., Yun F., Sukovic T., Wong B., et al. Frequency of CYP2C9 polymorphisms affecting warfarin metabolism in a large anticoagulant clinic cohort. Clin Biochem 39 (2006) 606-612
23. Yacobi A., Udall J.A., and Levy G. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect. Clin Pharmacol Ther 19 (1976) 552-558
24. Piroli R.J., Passananti G.T., Shively C.A., and Vesell E.S. Antipyrine and warfarin disposition in a patient with idiopathic hypoalbuminemia. Clin Pharmacol Ther 30 (1981) 810-816
25. Obayashi K., Nakamura K., Kawana J., Ogata H., Hanada K., Kurabayashi M., et al. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients. Clin Pharmacol Ther 80 (2006) 169-178
26. Kimura R., Miyashita K., Kokubo Y., Akaiwa Y., Otsubo R., Nagatsuka K., et al. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients. Thromb Res 120 (2007) 181-186
27. Miao L., Yang J., Huang C., and Shen Z. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients. Eur J Clin Pharmacol 63 (2007) 1135-1141
28. Mushiroda T., Ohnishi Y., Saito S., Takahashi A., Kikuchi Y., Saito S., et al. Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. J Hum Genet 51 (2006) 249-253
29. Cho H.J., Sohn K.H., Park H.M., Lee K.H., Choi B., Kim S., et al. Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics 8 (2007) 329-337
30. Herman D., Locatelli I., Grabnar I., Peternel P., Stegnar M., Mrhar A., et al. Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 5 (2005) 193-202
31. Caldwell M.D., Berg R.L., Zhang K.Q., Glurich I., Schmelzer J.R., Yale S.H., et al. Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 5 (2007) 8-16
32. Takahashi H., Wilkinson G.R., Nutescu E.A., Morita T., Ritchie M.D., Scordo M.G., et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 16 (2006) 101-110